You are here: Home » News-CM » Companies » News
Business Standard

Wockhardt announces successful USFDA inspection of Bioequivalence Centre in Aurangabad

Capital Market 

announced that U. S. ('USFDA') has carried out of Centre located at R&D Centre, Aurangabad during which studies of 0.4mg capsules and Tartrate 200mg ER tablets were audited.

At the end of inspection, there was Nil observation (i.e. zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations. This outcome would lead approvals of ANDAs in pipeline for which studies are being or will be done in the said Centre.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, April 15 2019. 09:44 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU